Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma

Chimeric antigen receptor (CAR) T cell therapy has become a new mainstay in the treatment of several hematologic malignancies, but the spectrum of associated complications is still incompletely defined. Here, we report the case of a 70-year-old female patient treated with tisagenlecleucel for diffus...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-05, Vol.13, p.1149450
Main Authors: Zundler, Sebastian, Vitali, Francesco, Kharboutli, Soraya, Völkl, Simon, Polifka, Iris, Mackensen, Andreas, Atreya, Raja, Neurath, Markus F, Mougiakakos, Dimitrios
Format: Article
Language:English
Subjects:
CAR T cells
case report
diffuse large B cell lymphoma
inflammatory bowel disease (IBD)
Oncology
tisagenlecleucel
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chimeric antigen receptor (CAR) T cell therapy has become a new mainstay in the treatment of several hematologic malignancies, but the spectrum of associated complications is still incompletely defined. Here, we report the case of a 70-year-old female patient treated with tisagenlecleucel for diffuse large B cell lymphoma (DLBCL), who developed chronic diarrhea with characteristics of inflammatory bowel disease (IBD)-like colitis. CAR T cells were substantially enriched in the colon lamina propria and other diagnoses were ruled out. Thus, we conclude that IBD-like colitis in this patient was associated to CAR T cell therapy and needs to be considered as a rare potential complication.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1149450